| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:PACOCF3;1,1,1-Trifluoro-2-heptadecanone
CAS:141022-99-3
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
Wuhan TCASChem Technology Co., Ltd.
|
| Tel: |
027-027-86697669 13986148687 |
| Email: |
sales@tcaschem.com |
| Products Intro: |
CAS:141022-99-3
Purity:97% Package:5g,10g,25g,100g
|
PACOCF3 manufacturers
- PACOCF3
-
- $39.00 / 5mg
-
2024-11-11
- CAS:141022-99-3
- Min. Order:
- Purity: 99.57%
- Supply Ability: 10g
|
| | PACOCF3 Basic information |
| | PACOCF3 Chemical Properties |
| Boiling point | 329.0±37.0 °C(Predicted) | | density | 0.955±0.06 g/cm3(Predicted) | | RTECS | MI3927000 | | Fp | 14℃ | | storage temp. | −20°C | | solubility | Soluble in DMSO | | form | Liquid | | color | White to off-white |
| Hazard Codes | Xi,F | | Risk Statements | 36/37/38-11 | | Safety Statements | 26-36-16 | | RIDADR | UN1170 - class 3 - PG 2 - Ethanol, solution | | WGK Germany | 3 |
| | PACOCF3 Usage And Synthesis |
| Description | PTK is an analog of palmitic acid in which the COOH group is replaced by trifluoromethyl ketone. In P388D1 cells, PTK inhibits iPLA2 activity with an IC50 value of 3.8 μM. A related compound, ATK is a less potent inhibitor of iPLA2 with an IC50 value of 15 μM. PTK also inhibits the activity of cPLA2 with an IC50 value almost identical to that of ATK. | | Uses | PACOCF3 is an inductors of BLM, an artificial lipid membranes and liposome permeabilization. Phospholipase A2 inhibitor. | | Definition | ChEBI: Palmityl Trifluoromethyl Ketone is an alpha-haloketone. | | Biological Activity | Phospholipase A 2 inhibitor. Can also alter Ca 2+ signaling in renal tubular cells. | | references | 1. murakami m et al.emerging roles of secreted phospholipase a2 enzymes: the 3rd edition.biochimie. 2014 sep 16. pii: s0300-9084(14)00252-1.2. quach nd et al. secretory phospholipase a2 enzymes as pharmacological targets for treatment of disease. biochem pharmacol. 2014 aug 15;90(4):338-48. 3. chalimoniuk m. secretory phospholipase a2 and its role in oxidative stress and inflammation]. postepy biochem. 2012;58(2):204-8.4. persaud sj.et al. the role of arachidonic acid and its metabolites in insulin secretion from human islets of langerhans. diabetes. 2007 jan;56(1):197-203.5. khakpour h et al. lipoprotein-associated phospholipase a2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. cardiol rev. 2009 sep-oct;17(5):222-9. 6. narendra sharath chandra jn1 et al. chemistry and structural evaluation of different phospholipase a2 inhibitors in arachidonic acid pathway mediated inflammation and snake venom toxicity. curr top med chem. 2007;7(8):787-800.7. packard cj. lipoprotein-associated phospholipase a2 as a biomarker of coronary heart disease and a therapeutic target. curr opin cardiol. 2009 jul;24(4):358-63.8. lucas r et al. synthesis and enzyme inhibitory activities of a series of lipidic diamine and aminoalcohol derivatives on cytosolic and secretory phospholipases a2. bioorg med chem lett. 2000 feb 7;10(3):285-8. |
| | PACOCF3 Preparation Products And Raw materials |
|